---
document_datetime: 2026-01-21 16:32:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/liprolog.html
document_name: liprolog.html
version: success
processing_time: 0.3190523
conversion_datetime: 2026-01-22 21:26:13.370452
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Liprolog

[RSS](/en/individual-human-medicine.xml/66998)

##### Authorised

This medicine is authorised for use in the European Union

insulin lispro Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Liprolog is a range of insulin medicines used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled, including patients whose diabetes has just been diagnosed. Liprolog medicines contain the active substance insulin lispro on its own or combined with protamine to make it longer acting:

- Liprolog (100 units/ml): standard-strength insulin lispro (fast-acting);
- Liprolog (200 units/ml): high-strength insulin lispro (fast-acting);
- Liprolog Mix25 (100 units/ml): 25% insulin lispro (fast-acting) and 75% insulin lispro protamine (longer-acting);
- Liprolog Mix50 (100 units/ml): 50% insulin lispro (fast-acting) and 50% insulin lispro protamine (longer-acting).

Expand section

Collapse section

## How is Liprolog used?

Liprolog medicines are available as solutions or suspensions for injection in vials, cartridges or prefilled pens.

The medicines are given by injection under the skin of the upper arm, thigh, buttock or abdomen (belly). Liprolog 100 units/ml may also be given by continuous infusion under the skin using an insulin pump or by injection into a vein. Liprolog 200 units/ml, Liprolog Mix25 and Liprolog Mix50 should never be given into a vein.

The dose depends on the individual patient's needs and may be reduced in patients with reduced kidney or liver function. The medicines are normally given shortly before a meal, but can be given just after a meal if necessary.

Liprolog (100 or 200 units/ml) can be used with a longer-acting insulin or with sulphonylureas (a group of diabetes medicines that are taken by mouth).

Patients can inject themselves with this medicine if they have been trained appropriately.

Liprolog can only be obtained with a prescription. For more information about using Liprolog, see the package leaflet or contact your doctor or pharmacist.

## How does Liprolog work?

Diabetes is a disease in which the body does not produce enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. Liprolog is a replacement insulin which is very similar to the insulin made by the body.

The active substance in Liprolog, insulin lispro, is produced by a method known as 'recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced, which makes them able to produce insulin lispro.

Insulin lispro has a small difference from human insulin that allows it to be absorbed faster by the body so it can act shortly after injection. Liprolog Mix25 and Liprolog Mix50 contain both insulin lispro and a longer-acting form called insulin lispro protamine, which is absorbed more slowly so that it works for longer.

Liprolog works in the same way as naturally produced insulin and helps glucose from the blood to enter cells. By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.

## What benefits of Liprolog have been shown in studies?

Liprolog was originally studied in eight clinical trials including 2,951 patients with type 1 diabetes (when the body cannot produce insulin) or type 2 diabetes (when the body is unable to use insulin effectively). The effectiveness of Liprolog was compared with that of Humulin R (a soluble recombinant DNA human insulin), when added to long-acting insulins given once or twice a day.

The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, and 'fasting' blood glucose levels (measured when the patient had not eaten for at least eight hours). Liprolog and Humulin R had a similar effect on the control of diabetes, as measured by HbA1c and fasting glucose levels.

Studies also looked at the use of Liprolog in 542 patients aged between two and 19 years. The medicine's effects in the body were similar in both adults and children.

Studies on the use of Liprolog in combination with sulphonylureas showed that these medicines used together reduce HbA1c more than sulphonylureas used alone.

## What are the risks associated with Liprolog?

Liprolog may cause hypoglycaemia (low blood glucose levels) and must not be given to patients whose blood glucose is already low.

For the full list of side effects and restrictions with Liprolog, see the package leaflet.

## Why is Liprolog authorised in the EU?

Liprolog has been shown to effectively reduce glucose levels and is comparable to human insulin. The European Medicines Agency decided that Liprolog's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Liprolog?

When first marketing the high-strength Liprolog (200 units/ml), the company provided information for patients and healthcare professionals to advise them of the 2 strengths and on how to use them safely to avoid medication errors.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Liprolog have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Liprolog are continuously monitored. Side effects reported with Liprolog are carefully evaluated and any necessary action taken to protect patients.

## Other information about Liprolog:

Liprolog received a marketing authorisation valid throughout the EU on 1 August 2001.

Liprolog : EPAR - Medicine overview

Reference Number: EMA/418451/2018

English (EN) (135.31 KB - PDF)

**First published:** 26/09/2009

**Last updated:** 18/03/2020

[View](/en/documents/overview/liprolog-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-806)

български (BG) (160.08 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/bg/documents/overview/liprolog-epar-medicine-overview_bg.pdf)

español (ES) (135.69 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/es/documents/overview/liprolog-epar-medicine-overview_es.pdf)

čeština (CS) (158.26 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/cs/documents/overview/liprolog-epar-medicine-overview_cs.pdf)

dansk (DA) (134.75 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/da/documents/overview/liprolog-epar-medicine-overview_da.pdf)

Deutsch (DE) (139.3 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/de/documents/overview/liprolog-epar-medicine-overview_de.pdf)

eesti keel (ET) (133.61 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/et/documents/overview/liprolog-epar-medicine-overview_et.pdf)

ελληνικά (EL) (159.75 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/el/documents/overview/liprolog-epar-medicine-overview_el.pdf)

français (FR) (137.07 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/fr/documents/overview/liprolog-epar-medicine-overview_fr.pdf)

hrvatski (HR) (157.26 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/hr/documents/overview/liprolog-epar-medicine-overview_hr.pdf)

italiano (IT) (134.72 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/it/documents/overview/liprolog-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (174.87 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/lv/documents/overview/liprolog-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (156.86 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/lt/documents/overview/liprolog-epar-medicine-overview_lt.pdf)

magyar (HU) (157.01 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/hu/documents/overview/liprolog-epar-medicine-overview_hu.pdf)

Malti (MT) (161.03 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/mt/documents/overview/liprolog-epar-medicine-overview_mt.pdf)

Nederlands (NL) (135.3 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/nl/documents/overview/liprolog-epar-medicine-overview_nl.pdf)

polski (PL) (160.98 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/pl/documents/overview/liprolog-epar-medicine-overview_pl.pdf)

português (PT) (136.6 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/pt/documents/overview/liprolog-epar-medicine-overview_pt.pdf)

română (RO) (154.17 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/ro/documents/overview/liprolog-epar-medicine-overview_ro.pdf)

slovenčina (SK) (159.68 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/sk/documents/overview/liprolog-epar-medicine-overview_sk.pdf)

slovenščina (SL) (155.69 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/sl/documents/overview/liprolog-epar-medicine-overview_sl.pdf)

Suomi (FI) (133.54 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/fi/documents/overview/liprolog-epar-medicine-overview_fi.pdf)

svenska (SV) (133.78 KB - PDF)

**First published:**

26/09/2009

**Last updated:**

18/03/2020

[View](/sv/documents/overview/liprolog-epar-medicine-overview_sv.pdf)

## Product information

Liprolog: EPAR - Product Information

English (EN) (2.94 MB - PDF)

**First published:** 28/08/2009

**Last updated:** 21/01/2026

[View](/en/documents/product-information/liprolog-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-816)

български (BG) (3.31 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/bg/documents/product-information/liprolog-epar-product-information_bg.pdf)

español (ES) (3.27 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/es/documents/product-information/liprolog-epar-product-information_es.pdf)

čeština (CS) (3.69 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/cs/documents/product-information/liprolog-epar-product-information_cs.pdf)

dansk (DA) (3.12 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/da/documents/product-information/liprolog-epar-product-information_da.pdf)

Deutsch (DE) (3.16 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/de/documents/product-information/liprolog-epar-product-information_de.pdf)

eesti keel (ET) (2.57 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/et/documents/product-information/liprolog-epar-product-information_et.pdf)

ελληνικά (EL) (3.38 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/el/documents/product-information/liprolog-epar-product-information_el.pdf)

français (FR) (2.43 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/fr/documents/product-information/liprolog-epar-product-information_fr.pdf)

hrvatski (HR) (3.13 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/hr/documents/product-information/liprolog-epar-product-information_hr.pdf)

íslenska (IS) (3 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/is/documents/product-information/liprolog-epar-product-information_is.pdf)

italiano (IT) (2.88 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/it/documents/product-information/liprolog-epar-product-information_it.pdf)

latviešu valoda (LV) (3.24 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/lv/documents/product-information/liprolog-epar-product-information_lv.pdf)

lietuvių kalba (LT) (3.37 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/lt/documents/product-information/liprolog-epar-product-information_lt.pdf)

magyar (HU) (3.35 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/hu/documents/product-information/liprolog-epar-product-information_hu.pdf)

Malti (MT) (3.67 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/mt/documents/product-information/liprolog-epar-product-information_mt.pdf)

Nederlands (NL) (3.11 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/nl/documents/product-information/liprolog-epar-product-information_nl.pdf)

norsk (NO) (3.08 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/no/documents/product-information/liprolog-epar-product-information_no.pdf)

polski (PL) (2.45 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/pl/documents/product-information/liprolog-epar-product-information_pl.pdf)

português (PT) (3.26 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/pt/documents/product-information/liprolog-epar-product-information_pt.pdf)

română (RO) (2.67 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/ro/documents/product-information/liprolog-epar-product-information_ro.pdf)

slovenčina (SK) (3.36 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/sk/documents/product-information/liprolog-epar-product-information_sk.pdf)

slovenščina (SL) (2.82 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/sl/documents/product-information/liprolog-epar-product-information_sl.pdf)

Suomi (FI) (3.12 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/fi/documents/product-information/liprolog-epar-product-information_fi.pdf)

svenska (SV) (3.19 MB - PDF)

**First published:**

28/08/2009

**Last updated:**

21/01/2026

[View](/sv/documents/product-information/liprolog-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000315488 21/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Liprolog : EPAR - All Authorised presentations

English (EN) (26.94 KB - PDF)

**First published:** 06/11/2018

[View](/en/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_en.pdf-0)

[Other languages (24)](#file-language-dropdown-408)

български (BG) (76.44 KB - PDF)

**First published:**

06/11/2018

[View](/bg/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_bg.pdf-0)

español (ES) (22.5 KB - PDF)

**First published:**

06/11/2018

[View](/es/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_es.pdf-0)

čeština (CS) (56.37 KB - PDF)

**First published:**

06/11/2018

[View](/cs/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_cs.pdf-0)

dansk (DA) (30.05 KB - PDF)

**First published:**

06/11/2018

[View](/da/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_da.pdf-0)

Deutsch (DE) (28.89 KB - PDF)

**First published:**

06/11/2018

[View](/de/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_de.pdf-0)

eesti keel (ET) (29.61 KB - PDF)

**First published:**

06/11/2018

[View](/et/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_et.pdf-0)

ελληνικά (EL) (42 KB - PDF)

**First published:**

06/11/2018

[View](/el/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_el.pdf-0)

français (FR) (111.31 KB - PDF)

**First published:**

06/11/2018

[View](/fr/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_fr.pdf-0)

hrvatski (HR) (54.7 KB - PDF)

**First published:**

06/11/2018

[View](/hr/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_hr.pdf-0)

íslenska (IS) (23.85 KB - PDF)

**First published:**

06/11/2018

[View](/is/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_is.pdf-0)

italiano (IT) (37.15 KB - PDF)

**First published:**

06/11/2018

[View](/it/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_it.pdf-0)

latviešu valoda (LV) (77.51 KB - PDF)

**First published:**

06/11/2018

[View](/lv/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_lv.pdf-0)

lietuvių kalba (LT) (74.51 KB - PDF)

**First published:**

06/11/2018

[View](/lt/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_lt.pdf-0)

magyar (HU) (45.87 KB - PDF)

**First published:**

06/11/2018

[View](/hu/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_hu.pdf-0)

Malti (MT) (47.31 KB - PDF)

**First published:**

06/11/2018

[View](/mt/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_mt.pdf-0)

Nederlands (NL) (38.82 KB - PDF)

**First published:**

06/11/2018

[View](/nl/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_nl.pdf-0)

norsk (NO) (62.34 KB - PDF)

**First published:**

06/11/2018

[View](/no/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_no.pdf-0)

polski (PL) (58 KB - PDF)

**First published:**

06/11/2018

[View](/pl/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_pl.pdf-0)

português (PT) (66.84 KB - PDF)

**First published:**

06/11/2018

[View](/pt/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_pt.pdf-0)

română (RO) (73.4 KB - PDF)

**First published:**

06/11/2018

[View](/ro/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_ro.pdf-0)

slovenčina (SK) (48.13 KB - PDF)

**First published:**

06/11/2018

[View](/sk/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_sk.pdf-0)

slovenščina (SL) (43.45 KB - PDF)

**First published:**

06/11/2018

[View](/sl/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_sl.pdf-0)

Suomi (FI) (37.81 KB - PDF)

**First published:**

06/11/2018

[View](/fi/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_fi.pdf-0)

svenska (SV) (34.75 KB - PDF)

**First published:**

06/11/2018

[View](/sv/documents/all-authorised-presentations/liprolog-epar-all-authorised-presentations_sv.pdf-0)

## Product details

Name of medicine Liprolog Active substance insulin lispro International non-proprietary name (INN) or common name insulin lispro Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code

- A10AB04
- A10AD04

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilisation of diabetes mellitus.

## Authorisation details

EMA product number EMEA/H/C/000393 Marketing authorisation holder

Eli Lilly Nederland B.V.

Orteliuslaan 1000 3528 BD Utrecht Netherlands

Opinion adopted 26/04/2001 Marketing authorisation issued 01/08/2001 Revision 31

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Liprolog : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (460.22 KB - PDF)

**First published:** 21/01/2026

[View](/en/documents/procedural-steps-after/liprolog-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Liprolog : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (369.32 KB - PDF)

**First published:** 28/08/2009

**Last updated:** 21/01/2026

[View](/en/documents/procedural-steps-after/liprolog-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Liprolog-H-C-393-X-0092 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/CHMP/416298/2014

English (EN) (809.62 KB - PDF)

**First published:** 27/10/2014

**Last updated:** 27/10/2014

[View](/en/documents/variation-report/liprolog-h-c-393-x-0092-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Liprolog: EPAR - Procedural steps taken before authorisation

English (EN) (88.58 KB - PDF)

**First published:** 19/06/2006

**Last updated:** 19/06/2006

[View](/en/documents/procedural-steps/liprolog-epar-procedural-steps-taken-authorisation_en.pdf)

Liprolog : EPAR - Scientific Discussion

English (EN) (181.66 KB - PDF)

**First published:** 19/06/2006

**Last updated:** 19/06/2006

[View](/en/documents/scientific-discussion/liprolog-epar-scientific-discussion_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 21/01/2026

## Share this page

[Back to top](#main-content)